Date: 2013-12-10
Type of information: Licensing agreement
Compound: agents capable of altering the therapeutic effect of psychotropic substances (anti-depressants, anti-psychotics, psycho-stimulants, etc.)
Company: Theranexus (France) CEA (France) Bio-Modeling-Systems (France)
Therapeutic area: CNS diseases - Mental diseases
Type agreement: licensing
Action mechanism:
Disease:
Details: * On December 10, 2013, Theranexus, a biopharmaceutical company created as a CEA spin-off, has announced the signing of a licence agreement with the CEA and Bio-Modeling Systems (BMSystems). The agreement authorises the exploitation of agents capable of altering the therapeutic effect of psychotropic substances (anti-depressants, anti-psychotics, psycho-stimulants, etc.). The technology in question, born of collaborative research by the CEA and BMSystems and now licensed to Theranexus, constitutes a solid core of industrial property offering broad prospects for high-potential industrial applications.
Psychotropic medications are some of the most widely used drugs in the world, e.g. in France – where they represent 25% of prescriptions, and in the United States – where anti-depressants are the most-prescribed drugs for the 18-44 age group. In France, more than 40% of people over the age of 60 take at least one psychoactive substance per day. Yet only 30% of patients taking antidepressants describe overall improvement, whereas 70% of patients notice sexual dysfunctions. Thus, finding solutions to make these drugs safer and more effective is clearly a matter of serious consequence for public health. Theranexus focuses its activities on improving the risk benefit ratio for psychotropic medications in indications for which the medical needs remain largely unmet.
Financial terms:
Latest news:
